EMERYVILLE, Calif.--(BUSINESS WIRE)--Tethys Bioscience, Inc., a privately held company, announced today that the United States Patent and Trademark Office has granted the Company US Patent 7,723,050. The patent is directed to the company’s groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition. Notably, this patent was issued following an accelerated review procedure which enables innovators to receive a final decision within 12 months of application. The issued patent is a major milestone for Tethys and has potential applicability to other Tethys products in development.